WE CLAIM:

1. A pharmaceutical composition comprising an insulin and treprostinil, wherein the treprostinil concentration is from about 0.01 to about 30 μM.
2. The pharmaceutical composition of Claim 1, wherein the insulin is selected from the group consisting of human insulin, insulin lispro, insulin aspart and insulin glulisine.
3. The pharmaceutical composition of Claim 2, wherein the insulin is insulin lispro.
4. The pharmaceutical composition of any one of Claims 1-3, wherein the insulin concentration is from about 40 to about 500 IU/mL.
5. The pharmaceutical composition of any one of Claims 1-4, wherein the insulin concentration is about 100 IU/mL.
6. The pharmaceutical composition of any one of Claims 1-5, wherein the treprostinil concentration is from about 0.05 to about 26 μM.
7. The pharmaceutical composition of any one of Claims 1-6, further comprising one or more preservatives.
8. The pharmaceutical composition of Claim 7, wherein the one or more preservatives are selected from the group consisting of phenol, meta-cresol, and benzyl alcohol.
9. The pharmaceutical composition of Claim 8, wherein the preservative is meta-cresol.
10. The pharmaceutical composition of claim 9, wherein the meta-cresol concentration is from about 2.5 mg/mL to about 3.8 mg/mL.
11. The pharmaceutical composition of claim 10, wherein the meta-cresol concentration is about 3.15 mg/mL.
12. The pharmaceutical composition of any one of Claims 1-11, further comprising a tonicity agent.
13. The pharmaceutical composition of Claim 12, wherein the tonicity agent is selected from the group consisting of glycerol and sodium chloride.
14. The pharmaceutical composition of Claim 13, wherein the tonicity agent is glycerol.
15. The pharmaceutical composition of Claim 14, wherein the glycerol concentration is from about 5 to about 20 mg/mL.
~~16. The pharmaceutical composition of Claim 15, wherein the glycerol concentration is about 16 mg/mL.~~
~~17~~16. The pharmaceutical composition of any one of Claims 1-~~16~~15, further comprising one or more stabilizing agents.

~~18~~17. The pharmaceutical composition of Claim ~~17~~16, wherein the one or more stabilizing agents are selected from the group consisting of zinc, sodium chloride, calcium chloride, and arginine.

~~19~~18. The pharmaceutical composition of Claim ~~18~~17, wherein the stabilizing agent is zinc.

~~20~~19. The pharmaceutical composition of Claim ~~19~~18, wherein the concentration of zinc is from about 0.00525 mg/mL to about 0.131 mg/mL.

~~21. The pharmaceutical composition of Claim 20, wherein the concentration of zinc is about 0.0197 mg/mL.~~

~~22~~20. The pharmaceutical composition of any one of Claims 1-~~21~~19, further comprising a buffering agent.

~~23. The pharmaceutical composition of Claim 22, wherein the buffering agent is selected from the group consisting of sodium phosphate, TRIS or sodium acetate.~~

~~24. The pharmaceutical composition of Claim 23, wherein the buffering agent is either sodium phosphate or TRIS.~~

~~25~~21. The pharmaceutical composition of any one of Claims 1-~~24~~20, wherein the pH of the composition is from about 7.0 to about 7.8.

~~26~~22. The pharmaceutical composition of any one of Claims 1-~~25~~21, wherein the pH of the composition is about 7.4.

~~27. The pharmaceutical composition of any one of Claims 1-26, wherein the insulin is insulin lispro, the preservative is meta-cresol, the tonicity agent is glycerol, the stabilizing agent is zinc and the buffering agent is either sodium phosphate or TRIS.~~

~~28~~23. ~~The~~ A pharmaceutical composition ~~of Claim 27, wherein the~~comprising:

a. insulin lispro, in a concentration ~~is~~ from about 40 to about 500 IU/mL,
b. treprostinil, in a concentration ~~is~~ from about 0.01 to about 30 μM,
c. meta-cresol, in a concentration ~~is~~ from about 2.5 to about 3.8 mg/mL,
d. glycerol, in a concentration ~~is~~ from about 5 to about 20 mg/mL,
e. zinc, in a concentration ~~is~~ from about 0.00525 to about 0.131 mg/mL, and
f. the pH of the composition is from about 7.0 to about 7.8.

~~29~~24. The pharmaceutical composition of Claim ~~28~~23, wherein the:

~~a.~~ insulin lispro concentration is about 100 IU/mL~~,~~;

~~b.~~ treprostinil concentration is from about 0.05 to about 26 μM~~,~~;

~~c. zinc concentration is about 0.0197 mg/mL,~~

~~d.~~ meta-cresol concentration is about 3.15 mg/mL~~,~~; and

~~e. glycerol concentration is about 16 mg/mL, and~~

~~f.~~ the pH of the composition is about 7.4.

~~30~~25. Use of a pharmaceutical composition of any one of Claims 1-24 in the manufacture of a medicament for the treatment ~~A method~~ of ~~treating~~ diabetes ~~comprising administering to a human in need thereof an effective dose of the pharmaceutical composition of any one of Claims 1-29~~.

~~31~~26. The pharmaceutical composition of any one of Claims 1-~~29~~24 for use in therapy.

~~32~~27. The pharmaceutical composition of any one of Claims 1-~~29~~24 for use in the treatment of diabetes.

~~33~~28. An article of manufacture comprising any one of the pharmaceutical compositions of Claims 1-~~29~~24.

~~34~~29. The article of manufacture of Claim ~~33~~-28 which is a multi-use vial.

~~35~~30. The article of manufacture of Claim ~~34~~-28 which is a re-usable pen injector.

~~36~~31. The article of manufacture of Claim ~~35~~-28 which is a pump device for continuous subcutaneous insulin infusion therapy.

~~37. An insulin for use in combination with treprostinil.~~

~~38. Treprostinil for use in combination with an insulin.~~